ABN Amro Investment Solutions Cuts Holdings in Zimmer Biomet Holdings, Inc. $ZBH

ABN Amro Investment Solutions decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 66.7% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 7,748 shares of the medical equipment provider’s stock after selling 15,516 shares during the quarter. ABN Amro Investment Solutions’ holdings in Zimmer Biomet were worth $701,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ZBH. Dodge & Cox raised its position in shares of Zimmer Biomet by 1.3% in the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after acquiring an additional 290,676 shares in the last quarter. Vanguard Group Inc. grew its holdings in Zimmer Biomet by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after purchasing an additional 192,517 shares during the last quarter. State Street Corp grew its holdings in Zimmer Biomet by 2.3% in the fourth quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after purchasing an additional 195,214 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after purchasing an additional 2,017,857 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider’s stock valued at $468,821,000 after purchasing an additional 36,611 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity

In related news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.28% of the stock is currently owned by insiders.

Zimmer Biomet Price Performance

Shares of ZBH opened at $91.35 on Friday. The firm has a market capitalization of $17.67 billion, a PE ratio of 23.73, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29. The company’s fifty day moving average price is $87.90 and its 200-day moving average price is $89.81.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. During the same quarter last year, the business posted $1.81 EPS. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Wells Fargo & Company lowered their price objective on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 target price on Zimmer Biomet in a research report on Wednesday, April 29th. Weiss Ratings cut Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, July 20th. Stifel Nicolaus lowered their price target on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Finally, Citizens Jmp dropped their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $100.70.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.